About Mandolin
Mandolin is a healthcare technology company that builds AI automation for specialty drug access. Its platform is designed for infusion providers, specialty pharmacies, and health systems, and works within the electronic health record (EHR) or pharmacy systems those organizations already use. The company’s stated goal is to help treatments reach patients sooner by reducing the administrative work between a referral and the start of therapy.
The platform automates referral intake, benefits verification, and prior authorization. It reads referrals, laboratory results, and clinical notes arriving through electronic prescriptions, fax, or email, then enters information into the customer’s existing system. It checks medical and pharmacy benefits through payer portals and phone calls, estimates patient costs, and compares chart information with payer criteria before submitting and tracking authorization requests.
Mandolin also describes workflows for identifying missing information and exceptions that need human attention. Its materials say the system can stop for review when a dose, diagnosis, or site-of-care detail requires a decision, and that customers can set rules for cases that should always be returned to their teams. The company says actions and reviews are logged, and that its system is built and overseen by pharmacists and clinicians with experience in this work.
Mandolin’s customers are organizations involved in delivering specialty medications, including infusion providers, specialty pharmacies, and health systems. The company presents its software as a way to reduce manual operational tasks while helping teams monitor referral turnaround, authorization status, denials, and incomplete prescriptions. Its website reports serving more than 250,000 patients across all 50 states; that figure is a company-reported measure.
Mandolin says its work is motivated by the delays patients can face while administrative requirements are handled. The company’s website describes its origin in the experience of its CEO Will’s grandfather, who did not begin treatment after an Alzheimer’s diagnosis because starting care proved difficult. Mandolin says it is building toward a future in which patients can start treatment as soon as they are ready.
The company is operated as Coral Automation, Inc. and is based in San Francisco, California. Its current company materials identify Will Yin and Rohit Rustagi as founders, and its LinkedIn company profile lists 2024 as its founding year. The company’s website states that it has raised $40 million and that its Series A was led by Greylock.
Mandolin describes its team as combining engineers working on AI systems with pharmacists and clinicians experienced in specialty pharmacy and infusion operations. Its published values include building quickly and incorporating feedback, candid communication, collaboration without silos, and taking responsibility for the quality and downstream impact of work. The company characterizes its culture as ambitious and collaborative, while emphasizing the practical importance of healthcare operations.
